AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
One hundred and twenty-three moderate-to-severe acne patients were enrolled in this trial at 15 sites located within the USA.
- One hundred and twenty-three moderate-to-severe acne patients were enrolled in this trial at 15 sites located within the USA.
- Patients were washed out of prior therapy and no concomitant therapy was permitted during the trial.
- The primary endpoint of this trial was mean change in facial inflammatory lesion count at week 12 relative to baseline.
- Baseline clinical assessments were conducted for each patient at screening and on Day 1 prior to imsidolimab dosing.